verapamil has been researched along with tamsulosin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bressel, HU; Goepel, M; Michel, MC; Rübben, H | 1 |
| Akino, H; Aoki, Y; Ito, H; Miwa, Y; Oyama, N; Yokoyama, O | 1 |
1 review(s) available for verapamil and tamsulosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for verapamil and tamsulosin
| Article | Year |
|---|---|
A 6-month large-scale study into the safety of tamsulosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Interactions; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Time Factors; Verapamil | 2001 |
5 other study(ies) available for verapamil and tamsulosin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure.
Topics: Administration, Intravesical; Administration, Topical; Adrenergic alpha-Antagonists; Animals; Atropine; Benzilates; Calcium Channel Blockers; Cholinergic Antagonists; Dinoprostone; Disease Models, Animal; Female; Injections, Intra-Arterial; Muscarinic Antagonists; Muscle Contraction; omega-Conotoxins; Oxytocics; Pressure; Rats; Rats, Sprague-Dawley; Sulfonamides; Tamsulosin; Treatment Outcome; Urethra; Urinary Bladder; Urinary Bladder, Overactive; Verapamil | 2007 |